









Markets
/
Stocks
/
nasdaq-piii
/

P3 Health Partners Inc

PIII

8.410USD

-0.050-0.59%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

27.48MMarket Cap

LossP/E TTM



P3 Health Partners Inc

8.410

-0.050-0.59%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of P3 Health Partners Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

P3 Health Partners Inc's Score

Industry at a Glance

Industry Ranking

200 / 407

Overall Ranking

368 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.667

Target Price

+61.54%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

P3 Health Partners Inc Highlights

StrengthsRisks

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from more than 250 disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 2,800 affiliated primary care providers across the country. Its local teams of health care professionals manage the care of thousands of patients in 23 counties across five states.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 42.97% year-on-year.

Overvalued

The company’s latest PE is -0.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 347.81K shares, decreasing 58.20% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 38.36K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 5.48, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 355.79M, representing a year-over-year decrease of 6.16%, while its net profit experienced a year-over-year decrease of 69.40%.

Score

Industry at a Glance

Previous score

5.48

Change



Financials

4.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.50

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

3.21

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

P3 Health Partners Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.63, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.18, which is -90.39% below the recent high of -0.02 and -1197.13% above the recent low of -2.31.

Score

Industry at a Glance

Previous score

7.63

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 200/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for P3 Health Partners Inc is 13.00, with a high of 20.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.667

Target Price

+61.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

P3 Health Partners Inc

PIII

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 3.52, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 9.10 and the support level at 8.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.37

Change

0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.136

Neutral

RSI(14)

43.748

Neutral

STOCH(KDJ)(9,3,3)

19.975

Sell

ATR(14)

0.327

Low Volatility

CCI(14)

-144.058

Sell

Williams %R

98.876

Oversold

TRIX(12,20)

-0.071

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

8.645

Sell

MA10

8.723

Sell

MA20

8.841

Sell

MA50

8.768

Sell

MA100

7.748

Buy

MA200

8.269

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 10.64%, representing a quarter-over-quarter decrease of 85.47%. The largest institutional shareholder is The Vanguard, holding a total of 38.36K shares, representing 1.17% of shares outstanding, with 5.07% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Chicago Pacific Founders UGP LLC

1.54M

Leavitt Equity Partners II LP

356.27K

+81.05%

Alyeska Investment Group, L.P.

180.91K

-0.00%

Bacchus (Amir)

45.13K

The Vanguard Group, Inc.

Star Investors

38.36K

+5.42%

Corient Private Wealth LLC

35.37K

-5.44%

Abdou (Sherif)

32.16K

EMFO, LLC

28.55K

+39.80%

Trinity Financial Advisors LLC

26.68K

+4.62%

Wasson (Gregory D)

21.36K

+10.33%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.22, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.83. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.